National Health Act (Pharmaceutical Benefits – Early Supply) Amendment September 2011 - specification under subsection 84AAA(2) (No. PB 64 of 2011)

Overview

The National Health Act 1953, enacted by the Australian Parliament, addresses the provision of health services and the regulation of pharmaceuticals, among other health-related matters. The National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 – specification under subsection 84AAA(2) PB 64 of 2011, made under the authority of subsection 84AAA(2) of the Act, amends the earlier instrument to adjust the list of pharmaceutical items for which Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements will not apply for early supplies. The objective of this amendment is to refine the list of pharmaceutical items by removing one and adding another, thereby aligning the list with current medical and policy recommendations. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended these changes based on its expertise in health economics, pharmacology, and clinical practice. This legislative instrument ensures that the list of pharmaceutical items in the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 reflects contemporary medical needs and practices.

Scope and Application

The National Health Act 1953 (the Act) governs the Pharmaceutical Benefits Scheme (PBS) and regulates the supply of pharmaceutical benefits in Australia. The Act applies to all persons and entities involved in the supply of pharmaceutical benefits under the PBS, including pharmaceutical manufacturers, wholesalers, and retailers, as well as healthcare providers and patients. The Act has a national jurisdictional reach, applying across all states and territories of Australia. The Act's authority to amend the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, which specifies pharmaceutical items for which PBS Safety Net entitlements will not apply for early supplies, stems from subsection 84AAA(2) of the Act. This legislative instrument, made under subsection 84AAA(2), amends the existing Instrument to delete an existing pharmaceutical item and add a new pharmaceutical item. The Pharmaceutical Benefits Advisory Committee (PBAC) recommended these changes, and the amendment is effective from 1 September 2011. The Act allows for further specification of the application of the legislation through subordinate instruments, which can include additional details such as circumstances for supply or other relevant factors.

Key Provisions

The National Health (Pharmaceutical Benefits – Early Supply) Amendment (September 2011) Instrument, made under the National Health Act 1953, primarily amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 (PB 30 of 2009) by deleting an existing pharmaceutical item and adding a new one (subsection 84AAA(2)). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended this amendment to reflect the latest considerations regarding early supply of pharmaceutical benefits. Specifically, the amendment removes the pharmaceutical item with the listed drug ‘Cimetidine’ in tablet form, 200 mg, administered orally, and adds the pharmaceutical item with the listed drug ‘Clopidogrel’ in tablet form, 75 mg, also administered orally. The Act imposes specific obligations on the parties involved. The Pharmaceutical Benefits Advisory Committee must make recommendations to the Minister about the contents of the instrument under subsection 84AAA(2), ensuring that the advice encompasses the perspectives of consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists, and specialists. The Minister, in turn, must consider these recommendations when making amendments to the list of pharmaceutical items specified in the instrument. The PBAC’s recommendations are integral in guiding these legislative changes, ensuring they are grounded in comprehensive and diverse expertise. Under this legislative instrument, an early supply of a pharmaceutical benefit is defined as a supply made within 20 days after the day of a previous supply to the same person of the same pharmaceutical benefit or another benefit with the same pharmaceutical item, or a benefit that is Schedule equivalent, provided the supply does not result from a prescription originating from a hospital (subsection 84AAA(1)). The Act mandates that supplies of specified pharmaceutical items do not accrue PBS Safety Net entitlements if they meet the criteria for early supply as outlined above. Breaches of the provisions outlined in this Act can lead to civil or criminal consequences. While the explanatory statement does not specify particular penalties, general provisions within the National Health Act 1953 or related legislation may impose fines or other penalties for non-compliance. The exact penalties would depend on the specific nature and severity of the breach, as well as the applicable laws at the time of the offence.